SmithKline Beecham Pharmaceuticals, UK
| Държава: | ----- |
| Кратка информация: | Broadening and balancing our portfolio, and moving away from a reliance on 'white pills/western markets'. We are diversifying our business to create a more balanced product portfolio and move away from a reliance on traditional ‘white pill, western markets.’ Sales generated from these markets and products have decreased from 40% in 2007, to 25% in 2010. Over time this should help to reduce the adverse impact of patent expirations on the Group. We expect to generate future sales growth by strengthening our core pharmaceuticals business and supplementing it with increased investment in growth areas such as emerging markets, vaccines, Japan, dermatology and Consumer Healthcare. Sales in Emerging Markets were up 22%, vaccines up 15%, Japan up 14%, dermatology up 6% (on a pro-forma basis excluding 2010 acquisitions) and Consumer Healthcare up 5% for 2010. Our plansAndrew Witty Drive growth in the pharmaceutical business in our core markets Fulfil the potential of Emerging Markets Expand our business in Japan Build our leadership in dermatology Grow the Vaccines and Consumer Healthcare business |
| Сайт: | http://www.gsk.com/ |
